Geisinger Health System’s $0 co-pay drug program for its chronically ill employee population is associated with positive cost savings and a 5-year return-on-investment of approximately 1.8.
James M. Pitcavage, MSPH
Advertisement
Articles by James M. Pitcavage, MSPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
3
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
4
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
5